FDA Withdraws Approval for GSK's Leucovorin in Treating Cerebral Folate Deficiency

U.S. Food and Drug Administration (FDA) announced the withdrawal of approval for leucovorin, a product from GlaxoSmithKline (GSK), used to treat cerebral folate deficiency. Cerebral folate deficiency is a rare neurological disorder characterized by low levels of folate in the brain, which can lead to developmental delays and other symptoms.

The disorder is distinct from other conditions. The company confirmed that the withdrawal of approval was planned from the outset of the drug's accelerated approval process. Leucovorin received accelerated approval based on evidence that it increased folate levels in the cerebrospinal fluid of patients with the disorder.

This approval pathway allows for conditional marketing while further confirmatory trials are conducted.

folate deficiency affects a small number of individuals, often diagnosed in childhood, and can result in seizures, motor impairments, and cognitive challenges.

The condition arises from issues in transporting folate across the blood-brain barrier, despite normal blood folate levels. Leucovorin, a form of folic acid, was approved to address this transport deficiency by providing an alternative pathway for folate entry into the brain.

The accelerated approval was granted under the FDA's provisions for rare diseases, where traditional clinical trials may be limited by the small patient population.

GSK's product, marketed as a specific formulation for this use, targeted patients with confirmed cerebral folate deficiency. The withdrawal follows the FDA's review process for such approvals, which requires post-approval studies to verify clinical benefits.

The planned withdrawal aligns with the terms of the initial approval, as confirmatory studies did not demonstrate the required clinical efficacy beyond biomarker improvements.

The FDA's decision means leucovorin will no longer be approved specifically for cerebral folate deficiency, though it remains available for other approved indications, such as in cancer chemotherapy. Patients currently using the drug for this condition may need to consult healthcare providers for alternative management options.

The stakes involve access to treatment for a vulnerable group with limited options for this rare disorder.

Affected individuals and families may face disruptions in care, prompting discussions on off-label use or investigational therapies. Regulatory bodies and pharmaceutical companies continue to evaluate similar cases to balance innovation with evidence requirements.

Looking ahead, GSK has not detailed immediate plans for the drug in this context, but the FDA's action underscores the importance of confirmatory data in rare disease treatments.

Broader implications include potential shifts in how accelerated approvals are structured for orphan drugs.